Trials / Conditions / Epidermolysis Bullosa Simplex

Epidermolysis Bullosa Simplex

17 registered clinical trials studyying Epidermolysis Bullosa Simplex — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epid NCT07027345	BioMendics, LLC	Phase 2
Recruiting	A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized NCT06509984	Centre Hospitalier Universitaire de Nice	Phase 2
Recruiting	A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammat NCT06136403	Centre Hospitalier Universitaire de Nice	Phase 2
Completed	Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Si NCT05062070	BioMendics, LLC	Phase 1
Completed	INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa NCT04908215	InMed Pharmaceuticals Inc.	Phase 2
Unknown	The State of Sexual Development in Children With Inherited Epidermolysis Bullosa NCT05033574	National Medical Research Center for Children's Health, Russian Federation	—
Withdrawn	A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa NCT04213703	ProgenaBiome	—
Unknown	Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex NCT03453632	University Hospital, Toulouse	Phase 2 / Phase 3
Completed	To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullos NCT03472287	Castle Creek Pharmaceuticals, LLC	Phase 1
Completed	Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epi NCT03389308	Castle Creek Pharmaceuticals, LLC	Phase 2
Unknown	Computational Drug Repurposing for All EBS Cases NCT03269474	Joyce Teng	—
Terminated	Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS) NCT03154333	Castle Creek Pharmaceuticals, LLC	Phase 2
Unknown	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study NCT03016715	Premier Specialists, Australia	Phase 2
Completed	Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study NCT02960997	Stanford University	Phase 2
Completed	Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin NCT02592954	Johns Hopkins University	Phase 1
Unknown	Diacerin for the Treatment of Epidermolysis Bullosa Simplex NCT02470689	Tel-Aviv Sourasky Medical Center	Phase 2
Unknown	Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita NCT00936533	Uppsala University	Phase 2